Search the whole station
On March 3, 2025, Hengsai Bio's self-developed KSD-201 DC vaccine for advanced renal cell carcinoma was officially launched at Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology ("Wuhan Tongji Hospital").
View details
DC Vaccine for Nasopharyngeal Carcinoma [Medium Swelling] Completes First Patient Enrollment for Dosing
View details
Hengsai Biotechnology Wins the 13th China Innovation and Entrepreneurship Competition (Guangdong Region)
View details
Kousai Biological Dendritic Cell Vaccine Drug Production and Research Project Groundbreaking Ceremony Successfully Held
View details
Exploring the Mystery of EBV and Tumor 丨Hengsai Biotechnology Shows Its Elegance on the International Academic Stage Again
View details
2024 EHA | Prof. Chunrui Li: Focusing on China's original research power, the field of EBV-associated hematological oncology therapeutics is revitalized
View details
Preface: The dragon is in full bloom, welcome the spring, the elite gathered, the annual event. Looking back to 2023, it is to overcome difficulties and move forward; looking forward to 2024, it is to compete with a hundred boats and oar first. Accompanied by the spring breeze in April, Hengsai Bio held the 2024 Annual Meeting and Spring Tour Group Building Activity in Anji, Zhejiang Province Spring Prelude Annual Feast On April 12, all the staff in a relaxed and happy atmosphere...
View details
China's First! Hengsai Bio's Original DC Vaccine KSD-101 Receives FDA IND Approval
View details
Hengsai Biologicals Completes Tens of Millions of Dollars in Series A+ Financing
View details
Hengsai Biotechnology
